A Review of Ferric Pyrophosphate Citrate (Triferic) Use in Hemodialysis Patients
| Autor: | Akram Al-Makki, Rabih Kalakeche, Brian Shepler, Tyler Albright |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Stage 5 chronic kidney disease Anemia Iron medicine.medical_treatment 030232 urology & nephrology 030204 cardiovascular system & hematology Placebo Gastroenterology Hemoglobins 03 medical and health sciences 0302 clinical medicine Renal Dialysis Internal medicine medicine FERRIC PYROPHOSPHATE CITRATE Humans Pharmacology (medical) Citrates Renal Insufficiency Chronic Pharmacology biology Transferrin saturation business.industry medicine.disease Diphosphates Ferritin Biochemistry Dietary Supplements Ferritins Hematinics biology.protein Administration Intravenous Hemodialysis Hemoglobin business |
| Zdroj: | Clinical Therapeutics. 38:2318-2323 |
| ISSN: | 0149-2918 |
| Popis: | Purpose The objective of this short review is to evaluate the efficacy of ferric pyrophosphate citrate and to determine its place in therapy based on the current published literature. Methods A literature search was conducted and pared down to yield 4 placebo controlled Phase II and III clinically relevant trials. Findings Ferric pyrophosphate citrate is a new intradialytic iron supplementation product that has been found to reduce the dose of erythropoiesis-stimulating agents and intravenous iron supplementation and to increase serum ferritin concentrations. Implications This agent may be administered to patients with stage 5 chronic kidney disease receiving hemodialysis as a new iron supplementation option to maintain hemoglobin, transferrin saturation, and ferritin concentrations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect